Cannell Capital Has Decreased By $7.55 Million Its Biotelemetry (BEAT) Stake; Vitae Pharmaceuticals (VTAE) Had 2 Bulls

October 6, 2017 - By Marguerite Chambers

Cannell Capital Llc decreased Biotelemetry Inc (BEAT) stake by 25.09% reported in 2017Q2 SEC filing. Cannell Capital Llc sold 228,803 shares as Biotelemetry Inc (BEAT)’s stock rose 13.43%. The Cannell Capital Llc holds 682,976 shares with $22.85 million value, down from 911,779 last quarter. Biotelemetry Inc now has $1.09B valuation. It is 0.00% or $0 reaching $33.65 per share. It is down 87.79% since October 6, 2016 and is uptrending. It has outperformed by 71.09% the S&P500.

Among 5 analysts covering Vitae Pharmaceuticals (NASDAQ:VTAE), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Vitae Pharmaceuticals had 7 analyst reports since August 8, 2015 according to SRatingsIntel. The rating was downgraded by JMP Securities on Thursday, August 4 to “Market Perform”. The stock of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) earned “Buy” rating by Stifel Nicolaus on Thursday, March 17. The stock of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. The firm earned “Sell” rating on Saturday, August 8 by Zacks. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. The stock of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) earned “Market Perform” rating by Wells Fargo on Thursday, September 15. Piper Jaffray downgraded the shares of VTAE in report on Wednesday, September 21 to “Neutral” rating. See Vitae Pharmaceuticals Inc (NASDAQ:VTAE) latest ratings:

Among 4 analysts covering BioTelemetry (NASDAQ:BEAT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry had 6 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was initiated by Dougherty & Company on Friday, December 2 with “Buy”. The company was maintained on Tuesday, April 11 by Dougherty & Company. The rating was maintained by Dougherty & Company with “Buy” on Tuesday, July 28. Sidoti initiated BioTelemetry, Inc. (NASDAQ:BEAT) on Tuesday, September 13 with “Buy” rating.

Cannell Capital Llc increased Jernigan Cap Inc stake by 16,353 shares to 161,100 valued at $3.54 million in 2017Q2. It also upped Liberty Tax Inc (NASDAQ:TAX) stake by 416,861 shares and now owns 557,015 shares. Veracyte Inc (NASDAQ:VCYT) was raised too.

Investors sentiment decreased to 1.3 in 2017 Q2. Its down 0.12, from 1.42 in 2017Q1. It dropped, as 18 investors sold BEAT shares while 58 reduced holdings. 41 funds opened positions while 58 raised stakes. 23.79 million shares or 8.10% more from 22.01 million shares in 2017Q1 were reported. 224,539 were accumulated by Driehaus Capital Mgmt Limited Liability Company. Bogle Invest Mgmt LP De accumulated 7,725 shares. Etrade Management Ltd holds 0.03% or 26,732 shares. White Pine Ltd Liability accumulated 0.24% or 18,575 shares. Perkins Capital Management Incorporated has 0.56% invested in BioTelemetry, Inc. (NASDAQ:BEAT). Globeflex Limited Partnership has 1.02% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 123,747 shares. The New York-based Blackrock has invested 0.01% in BioTelemetry, Inc. (NASDAQ:BEAT). Awm Inv Com reported 99,189 shares. Massachusetts Fincl Svcs Communications Ma invested 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). 1832 Asset Mngmt Lp holds 800 shares. Oppenheimer Asset Inc holds 7,170 shares or 0.01% of its portfolio. Moreover, Avalon Limited Liability Company has 0.04% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 34,913 shares. Hood River Capital Mngmt Ltd Liability Com stated it has 1.84% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Quantbot LP stated it has 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Credit Suisse Ag invested in 43,162 shares.

Analysts await BioTelemetry, Inc. (NASDAQ:BEAT) to report earnings on November, 1. They expect $0.28 EPS, up 33.33% or $0.07 from last year’s $0.21 per share. BEAT’s profit will be $9.07M for 30.04 P/E if the $0.28 EPS becomes a reality. After $0.23 actual EPS reported by BioTelemetry, Inc. for the previous quarter, Wall Street now forecasts 21.74% EPS growth.

It is down 0.00% since October 6, 2016 and is . It has underperformed by 16.70% the S&P500.